TERT promoter mutations (TERT-mut) are detectable in the majority of urothelial carcinomas. The detection of TERT-mut in urine is under investigation as a potential urine-based molecular-screening assay for bladder cancer. A small but significant number of bladder carcinomas are pure squamous cell carcinoma. We sought to assess the incidence of TERT-mut in squamous cell carcinoma of the urinary bladder. A retrospective search of the institutional pathology archives yielded 15 cystectomy specimens performed for squamous cell carcinoma (2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010)(2011)(2012)(2013)(2014). Histologic slides were reviewed by a senior urologic pathologist to confirm the diagnosis and select a representative formalin-fixed paraffin-embedded tissue block for mutational analysis. All cases yielded adequate material for DNA analysis. Sequencing for TERT-mut was performed using previously described SafeSeq technique. We detected TERT-mut in 12/15 (80%) of bladder squamous cell carcinomas. TERT promoter mutations, commonly found in conventional urothelial carcinoma, are also highly prevalent in urinary bladder squamous cell carcinoma suggesting a common tumorigenesis and potential utility as a molecular urine-basedscreening assay.
TERT promoter mutations (TERT-mut) are detectable in the majority of urothelial carcinomas. The detection of TERT-mut in urine is under investigation as a potential urine-based molecular-screening assay for bladder cancer. A small but significant number of bladder carcinomas are pure squamous cell carcinoma. We sought to assess the incidence of TERT-mut in squamous cell carcinoma of the urinary bladder. A retrospective search of the institutional pathology archives yielded 15 cystectomy specimens performed for squamous cell carcinoma (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) . Histologic slides were reviewed by a senior urologic pathologist to confirm the diagnosis and select a representative formalin-fixed paraffin-embedded tissue block for mutational analysis. All cases yielded adequate material for DNA analysis. Sequencing for TERT-mut was performed using previously described SafeSeq technique. We detected TERT-mut in 12/15 (80%) of bladder squamous cell carcinomas. TERT promoter mutations, commonly found in conventional urothelial carcinoma, are also highly prevalent in urinary bladder squamous cell carcinoma suggesting a common tumorigenesis and potential utility as a molecular urine-basedscreening assay. Modern Pathology (2016) 29, 511-515; doi:10.1038/modpathol.2016.53; published online 11 March 2016 Maintenance of telomeres is a critical function for cell survival and continued replication, and one mechanism by which cells maintain telomeres is through the action of an extension complex that adds telomeric repeats to the ends of chromosomes. 1 This complex includes the protein product of the telomerase reverse transcriptase (TERT) gene (5p15.33). High rates of activating mutations in the upstream promoter of the TERT gene (TERT-mut) have been found in several solid tumor types. [2] [3] [4] [5] Mutations tend to occur in 'hot spots', particularly g.1295228C4T and g.1295250C4T. These mutations generate a CCGGAA/T or GGAA/T motif, thereby altering the binding site for Ets transcription factor, thereby increasing TERT promoter activity. 2, 6, 7 Our group and others have demonstrated TERT-mut to be the most common genetic alterations in urothelial (transitional cell) carcinoma of the bladder and upper urinary tract. [8] [9] [10] [11] [12] [13] In the study by Kinde et al, 12 66% of muscle invasive and 74% of non-muscle invasive bladder lesions were shown to harbor these alterations.
Greater than 90% of bladder carcinomas are urothelial type. Squamous cell carcinoma, adenocarcinoma, and small cell carcinoma represent the remaining most common types. 14, 15 Recently, we investigated TERT-mut incidence in small cell carcinomas of the urinary bladder. 16 In the current study, we sought to determine the prevalence of TERT-mut in primary squamous cell carcinoma of the urinary bladder.
Materials and methods
A retrospective review was performed and the archives of a single institution were searched for cases of pure squamous cell carcinoma primary to the bladder treated by cystectomy, cystoprostatectomy, or other radical excision between the years 2000 and 2014. To ensure the inclusion of only 'pure' squamous cell carcinoma cases that would satisfy the World Health Organization/International Society of Urologic Pathology (WHO/ISUP 2004) definition of the entity, we limited our study to cystectomy and cystoprostatectomy specimens. All histologic slides were reviewed by a senior urologic pathologist to confirm the diagnosis of squamous cell carcinoma and select a representative tumor formalin-fixed paraffin-embedded block for mutational analysis. A total of 15 cases were included in the study based on the availability of formalin-fixed paraffin-embedded blocks with sufficient tumor for sampling. The tumor areas were cored with a sterile 16-gauge needle and the fraction of neoplastic cells was estimated from adjacent sections. The cores were placed in 1.5 ml sterile tubes for DNA purification.
Following DNA purification, samples were analyzed with Safe-SeqS, a sequencing error-reduction technology described previously, 17 which better discriminates genuine TERT-mut from artefactual sequencing variants introduced during the sequencing process. Safe-SeqS amplification primers were designed to amplify segments containing the region of the TERT promoter previously shown to harbor mutations in melanomas and other tumors (Figure 1 ). 12 The forward and reverse amplification primers contained the TERT-specific sequences at their 3′ ends and a universal priming site at their 5′ end. The reverse primer additionally contained a 14-base unique identifier comprised of 14 degenerate N bases (equal likelihood of being an A, C, T, or G) between the universal priming site and gene-specific sequences. The sequences of the forward and reverse primers were either 5 0 -CACACAGGAAACAGCTAT GACCATGGGCCGCGGAAAGGAAG and 5′-CGACG TAAAACGACGGCCAGTNNNNNNNNNNNNNNCG TCCTGCCCCTTCACC, or 5′CACACAGGAAACAGC TATGACCATGGCGGAAAGGAAAGGGAG and 5′-CG ACGTAAAACGACGGCCAGTNNNNNNNNNNNNN NCCGTCCCGACCCCTC. PCR products were purified with AMPure and sequenced on a MiSeq instrument. Data were analyzed as previously described. 17 Tumor samples were considered positive if the fraction of mutations exceeded 1% of alleles (which was a frequency at least 5 × higher than found in control DNA templates). All sequencing assays scored as positive were confirmed in at least one additional, independent PCR and sequencing experiment.
Two sets of negative control samples were also analyzed. Ninety-four peripheral blood samples from healthy population were tested for TERT-mut as negative PCR procedure controls. Eight formalinfixed paraffin-embedded benign transurethral bladder biopsy samples were also used as negative tissue controls.
Results

Patient Demographics, Clinicopathologic Features, and Outcome
This cohort included six females and nine males. The mean patient age was 65 years (range 51-83). None of the patients had associated schistosomiasis. The tumors were primarily centered in the bladder wall (12 patients) with the remaining in the trigone, bladder neck urethral region, and bladder dome. of note, one patient had a history of extrophy of the bladder and had a tumor that extended from the bladder wall to involve the dermis of the overlying abdominal wall. Two patients (13%) had lymph node metastases identified at the time of resection. Mean follow up time was 1564 days with a median follow up interval of 981 days (range 22-5459 days). Two patients (13%) died from disease at 337 and 169 days post surgery, the remaining 13 patients are presently disease free (Table 1) . Morphologically, all tumors demonstrated typical feature of conventional squamous cell carcinoma. Papillary architecture was observed in one squamous cell carcinoma, and focal sarcomatoid features were found in another case.
TERT Promoter Analysis
TERT-mut were identified in 12 out of 15 (80%) cases of squamous cell carcinoma. The majority of these (83%) were the conventional morphology, however both the papillary squamous cell carcinoma and squamous cell carcinoma with sarcomatoid features also had TERT-mut. Of all the patients with TERT-mut, 2 (17%) were g.1295250C4T and the remaining 10 (83%) were a g.1295228C4T alteration ( Table 2 ). Prevalence of TERT-mut in primary squamous cell carcinoma All of the blood and formalin-fixed paraffinembedded samples used as negative controls tested negative for TERT-mut.
Discussion
Bladder carcinoma is the most common malignancy of the urinary tract, and the fourth most common carcinoma in men in the Western world. Among bladder cancers, urothelial carcinoma is by far the most prevalent histologic type, with squamous cell carcinoma and adenocarcinoma making up o 5% of cases. 18 Per patient, the cost of bladder cancer management is the highest among all tumors, owing to the need for long-term monitoring with regular cystoscopy, imaging, and urine cytology. [19] [20] [21] TERT-mut were first reported in melanoma. 2 Subsequently, the same mutations were discovered by our group and others in numerous solid cancers, including urothelial carcinoma, gliomas and hepatocellular carcinoma. [3] [4] [5] High rates of TERT-mut have been conspicuously absent in colorectal and lung carcinomas. 3, 22 More recently, high rates of TERTmut have been demonstrated in small cell carcinoma of the urinary bladder, urothelial carcinoma with squamous differentiation, and nested variant of urothelial carcinoma. 13, 16, 22 These consistent genetic alterations, shared by urothelial carcinoma and several of its variants, offer further support for a common oncogenic pathways.
Our study is the first to evaluate the presence of TERT-mut in conventional squamous cell carcinoma of the urinary bladder. As noted above, TERT-mut have been described in several tumor types in the bladder with urothelial differentiation; however, the absence of urothelial differentiation in all 12 cases makes this study novel. All mutations were from previously published hotspots, with the majority of cases (83%) having the g.1295228C4T mutation, whereas the remainder had a g.1295250C4T mutation. Histologically, all 12 TERT-mut-positive tumors were invasive conventional squamous cell carcinoma and with one tumor showing focal sarcomatoid differentiation and a second demonstrating a papillary architecture. Of note, one of the three tumors that lacked TERT-mut was the only case in our cohort that was centered in the bulbar urethra. Evaluation of prognostic significance of TERT-mut was not feasible in this limited study.
Our found rate of 80% prevalence of TERT-mut in squamous cell carcinoma of bladder is comparable to the rate previously demonstrated in conventional urothelial carcinoma including those with only focal squamous differentiation. 9, 11, 12, 22 This high rate is in stark contrast to the lack of TERT-mut in cervical and pulmonary squamous carcinomas. 22 If further confirmed, the latter suggests a potential diagnostic role for identifying TERT-mut in assigning a primary urinary tract origin in cases where the differential include secondary involvement of bladder from such sites or cases of unknown primary. Finally, chronic bladder irritation (eg, stones, extrophy, and endemic Schistosomiasis) is associated with higher incidence of bladder squamous cell carcinoma. 18 To our knowledge, the presence of TERT-mut in squamous cell carcinoma tumors arising in the later setting has not been specifically examined. None of our current patients had associated schistosomiasis. One of our TERT-mut-positive tumors occurred in a patient with a history of bladder extrophy.
In summary, TERT promoter mutations, commonly found in conventional urothelial carcinoma, are also highly prevalent in urinary bladder squamous cell carcinoma, suggesting a common tumorigenesis and potential utility as a molecular urine-based-screening assay.
